Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer Prevention
November 09, 2022 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health,...
Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer
September 29, 2022 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and...
GENE Momentum building - a year in review
August 30, 2022 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in guideline driven genomics-based tests in health,...
GeneType launches Multi-Test in Obstetrics clinics with more than 1,000 referring primary care physicians
July 18, 2022 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, July 18, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and...
GeneType Risk Assessment Test onboarding in 16 clinics
July 01, 2022 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, July 01, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and...